Showing 1 - 7 results of 7 for search 'Josef S Smolen', query time: 0.02s Refine Results
  1. 1
    Era of biosimilars in rheumatology: reshaping the healthcare environment

    Era of biosimilars in rheumatology: reshaping the healthcare environment by Josef S Smolen, Joao Goncalves, Mark Quinn, Fabrizio Benedetti, Jake Yongkwon Lee

    Published 2019-05-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects

    Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects by Bruno Fautrel, Josef S Smolen, Fabrizio Benedetti, Roberto Caporali, Thomas Doerner, Burkhard Pieper, Minjun Jang

    Published 2021-06-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study

    Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study by Philip J Mease, Joachim Sieper, Josef S Smolen, Dafna Gladman, H Patrick McNeil, Maja Hojnik, Pascal Nurwakagari, John Weinman

    Published 2019-06-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

    Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment by Eugen Feist, Roy M. Fleischmann, Saeed Fatenejad, Daria Bukhanova, Sergey Grishin, Sofia Kuzkina, Michael Luggen, Evgeniy Nasonov, Mikhail Samsonov, Josef S. Smolen

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study

    Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study by Josef S Smolen, Yoshiya Tanaka, Paul Emery, Manish Jain, Koji Kato, Stanley B Cohen, Nasser Khan, William Rigby, Sebastian Meerwein, Juan Ignacio Vargas, Kyle M Carter, Charles Phillips

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis

    Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis by Gerd Burmester, Tsutomu Takeuchi, Josef S Smolen, Mark C Genovese, Masayoshi Harigai, Kevin Winthrop, Yi-Ming Chen, Tsu-Yi Hsieh, Chad Walls, Wen-Shuo Wu, Christina Dickson, Ran Liao

    Published 2020-02-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Roads to remission: evolving treatment concepts in type 2 inflammatory diseases

    Roads to remission: evolving treatment concepts in type 2 inflammatory diseases by Marek Lommatzsch, Katharina Blumchen, Lisa A. Beck, Jean Bousquet, Guy G. Brusselle, Wytske J. Fokkens, Eckard Hamelmann, Susanne Lau, Hagen Ott, Oliver Pfaar, Hugh A. Sampson, Josef S. Smolen, Christian Taube, Ingo H. Tarner, Martin Wagenmann, Thomas Werfel, Margitta Worm, Harald Renz

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: